Hanmi's New Story
Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi
Meet Us at ESMO 2026.
First-in-Human Study of BH3120, a novel 4-1BB×PD-L1 Bispecific Antibody, as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors: Results from Monotherapy Dose-Escalation Part
- Presentation Number
- 1962Ep
- Presenter
-
Hye Ryun Kim, M.D. /
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Phase I dose-ranging update with HM97662, a dual EZH1/2 inhibitor, in biomarker-selected advanced or metastatic solid tumors
- Presentation Number
- 1051P
- Presenter
-
Lisi Elizabeth Lim /
Department of Medical Oncology, Ballarat Regional Integrated Cancer Centre, Ballarat, Victoria, Australia
